Astellas Pharma (TSE:4503) EPS (Basic): 円162.77 (TTM As of Mar. 2026)


TSE:4503 Astellas Pharma Inc TSE:4503
81 GF Score
Price 円2,159.50
GF Value 円2,216.07
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma EPS (Basic)?

Astellas Pharma TSE:4503 +1.24% 81 EPS (Basic) is 円162.77 as of Mar. 2026. GuruFocus rates TSE:4503 with a GF Score™ of 81/100 and a GF Value™ of 円2,216.07 (Fairly Valued). The stock has 4 warning signs investors should review.

Astellas Pharma's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was 円24.29. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was 円162.77.

Astellas Pharma's EPS (Diluted) for the three months ended in Mar. 2026 was 円24.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円162.22.

Astellas Pharma's EPS without NRI for the three months ended in Mar. 2026 was 円24.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 160.35.

During the past 12 months, Astellas Pharma's average EPS without NRIGrowth Rate was 477.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was 43.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was -10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Astellas Pharma's highest 3-Year average EPS without NRI Growth Rate was 89.70% per year. The lowest was -55.40% per year. And the median was 6.95% per year.

Astellas Pharma  (TSE:4503) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Astellas Pharma EPS (Basic) Related Terms

Astellas Pharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma EPS (Basic) Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.08 54.24 9.51 28.35 162.77

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.84 38.22 44.22 56.04 24.29
TSE:4503
81GF Score
Astellas Pharma Inc TSE:4503
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Astellas Pharma's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(291535-0)/1791.105
=162.77

Astellas Pharma's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(43561-0)/1791.105
=24.32

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円162.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of 円162.77 mean?
Astellas Pharma (TSE:4503) has a EPS (Basic) of 円162.77 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's EPS (Basic) too high?
Astellas Pharma's current EPS (Basic) is 円162.77. Overall, Astellas Pharma has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's EPS (Basic) compare to LLY and JNJ?
Astellas Pharma's EPS (Basic) of 円162.77 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current EPS (Basic) is 円162.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (TSE:4503) is currently considered Fairly Valued. The stock's GF Value™ is 円2,216.07, compared to a current price of 円2,159.50 — trading 2.6% below its estimated fair value. The current EPS (Basic) is 円162.77. Astellas Pharma's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Astellas Pharma (TSE:4503), the current EPS (Basic) is 円162.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (TSE:4503) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of 円2,159.50 is trading 2.6% below its estimated GF Value™ of 円2,216.07. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for TSE:4503:

  • EPS (Basic): 円162.77
  • GF Value™: 円2,216.07 vs. price of 円2,159.50 (2.6% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the TSE:4503 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
81GF Score

Get the complete analysis for TSE:4503

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,159.50
Price
円2,216.07
GF Value